Viemed Healthcare Inc (VMD)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Viemed Healthcare Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 11.70 $ — 91% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 6.0% below the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.46 | 0.44 – 0.47 | 317 | – | 2 |
| 12/31/2027 | 0.61 | 0.58 – 0.64 | 361 | – | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.10 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.10 | 20.70 | 61 | 19.60 | 7.10 | 15 | 3 |
| 2025: Q1 | 0.06 | 59.60 | 59 | 16.90 | 4.40 | 3 | -13 |
| 2025: Q2 | 0.08 | 112.30 | 63 | 14.70 | 5.00 | 12 | 4 |
| 2025: Q3 | 0.09 | -8.80 | 72 | 24.00 | 4.90 | 18 | 11 |
| 2025: Q4 | 0.14 | 35.10 | 76 | 25.50 | 7.40 | 18 | 10 |
| 2026: Q1 | 0.06 | 1.10 | 75 | 27.50 | 3.40 | 8 | 1 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 31 | 0 | 1 | 0.03 | 6 | 13 | 25 |
| 2017 | 47 | 9 | 8 | 0.22 | 12 | 24 | 38 |
| 2018 | 65 | 17 | 10 | 0.26 | 22 | 35 | 54 |
| 2019 | 80 | 9 | 9 | 0.21 | 19 | 44 | 83 |
| 2020 | 131 | 27 | 32 | 0.78 | 35 | 82 | 113 |
| 2021 | 117 | 12 | 9 | 0.22 | 22 | 95 | 118 |
| 2022 | 139 | 8 | 6 | 0.16 | 28 | 97 | 117 |
| 2023 | 183 | 14 | 10 | 0.25 | 45 | 114 | 155 |
| 2024 | 224 | 18 | 11 | 0.28 | 39 | 131 | 177 |
| 2025 | 270 | 21 | 15 | 0.37 | 52 | 142 | 215 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Viemed Healthcare, Inc. bietet über seine Tochtergesellschaften medizinische Heimausstattung (HME) und postakute respiratorische Gesundheitsdienstleistungen in den USA an.
| Employees | 1,387 |
|---|---|
| Headquarters | Lafayette, LA |
| Address | 625 East Kaliste Saloom Road, 70508 Lafayette, United States |
| Phone | 337 504 3802 |
| Website | viemed.com |
| IPO Date | 22. Dec 2017 |
| ISIN | CA92663R1055 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Casey Hoyt | CEO & Director | 1977 |
| Michael B. Moore CRT | President | 1977 |
| Trae Paul Fitzgerald | Chief Financial Officer | 1988 |
| William Todd Zehnder | COO & Director | 1975 |
| Jeremy Trahan | Executive VP, General Counsel & Corporate Secretary | 1970 |
| William Dana Frazier M.D. | Chief Medical Officer & Director | 1958 |
| Jerome Richard Cambre II | Vice President of Sales | 1971 |
| Michael Freeman | Chief Business Development Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.